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Abstract
Purpose Patients with idiopathic pulmonary fibrosis (IPF)
show increased PET signal at sites of morphological abnor-
mality on high-resolution computed tomography (HRCT).
The purpose of this investigation was to investigate the PET
signal at sites of normal-appearing lung on HRCT in IPF.
Methods Consecutive IPF patients (22 men, 3 women) were
prospectively recruited. The patients underwent 18F-FDG
PET/HRCT. The pulmonary imaging findings in the IPF
patients were compared to the findings in a control population.
Pulmonary uptake of 18F-FDG (mean SUV) was quantified at
sites of morphologically normal parenchyma onHRCT. SUVs
were also corrected for tissue fraction (TF). The mean SUV in
IPF patients was compared with that in 25 controls (patients
with lymphoma in remission or suspected paraneoplastic
syndrome with normal PET/CT appearances).
Results The pulmonary SUV (mean±SD) uncorrected for
TF in the controls was 0.48±0.14 and 0.78±0.24 taken from
normal lung regions in IPF patients (p<0.001). The TF-
corrected mean SUV in the controls was 2.24±0.29 and
3.24±0.84 in IPF patients (p<0.001).
Conclusion IPF patients have increased pulmonary uptake
of 18F-FDG on PET in areas of lung with a normal morpho-
logical appearance on HRCT. This may have implications for
determining disease mechanisms and treatment monitoring.
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Introduction
Idiopathic pulmonary fibrosis (IPF) has an increasing inci-
dence and a prognosis worse than many cancers. There
remains no effective treatment. The current main role of
imaging in IPF has been the use of high-resolution computed
tomography (HRCT) both for diagnosis and monitoring.
However, the impact of HRCT on mortality in IPF is limited
[1–5]. There have been recent reports on the use of PET in
IPF. Increased pulmonary PET signal with various PET
tracers is now documented in IPF and other diffuse paren-
chymal pulmonary diseases (DPLD). These signal changes
have been related to regions of lung parenchymal changes on
HRCT [6–11]. However, to our knowledge, no studies have
addressed metabolic functional changes in morphologically
normal lung on HRCT in the setting of IPF. Identification of
abnormal PET signal in IPF, undetectable on HRCT, could
give an insight into the pathogenesis of the disease and may
permit earlier detection of changes in disease activity. The
latter could be important in disease monitoring. Sensitive
methods of disease monitoring in IPF patients are urgently
required, as a lack of early measurable endpoints is hamper-
ing drug development.
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For these reasons we measured the 18F-FDG uptake using
PET in regions of lung parenchyma with normal HRCT
appearances in IPF patients, and compared the uptake to that





Consecutive IPFpatients (22men, 3women; age 72.8±7.5 years,
mean ± SD) were prospectively recruited for 18F-FDG PET
imaging. All patients underwent full clinical assessment includ-
ing multidisciplinary team review, pulmonary function tests and
HRCT evaluation. Infection and neoplasia were excluded on
clinical and radiological grounds. The diagnosis of IPF was
made on clinical/radiological grounds following multi-
disciplinary team review. The clinical profiles of the patients
are summarized in Table 1. The study was approved by the
ethics board.
Control subjects
Due to the relatively high radiation exposure from 18F-FDG
PET/CT, normal volunteers were not used. Instead, two
patient groups were used as a control population: 15 patients
(7 men, 8 women; 63.9±11.4 years) undergoing 18F-FDG
PET/CT referred with neurological conditions to exclude
paraneoplastic syndrome (with negative findings) and
10 patients (5 men, 5 women; 59.1±10.4 years) with
extrathoracic lymphoma (1 Hodgkin’s lymphoma and 9
non-Hodgkin’s) in remission undergoing routine surveil-
lance off treatment. HRCTwas not performed in the control
population. All these patients were consecutively recruited
over 12 months. As the subjects in both groups were
expected to have healthy lung parenchyma, the lymphoma
and paraneoplasia subjects were combined into a single
control group (62.16±10.3 years) for comparison with IPF
patients.
PET/CT acquisition
All patients fasted for 6 h. Images were acquired 1 h after
injecting 200 MBq of 18F-FDG using a dedicated combined








1 M 74 56 51
2 M 56 99 N/A
3 M 75 61 69
4 M 72 41 N/A
5 M 86 75 37
6 M 73 98.9 68.6
7 M 73 89 42
8 M 71 101.1 N/A
9 M 76 91 59
10 M 74 70 N/A
11 M 74 63 34
12 M 81 67 N/A
13 M 56 62 26
14 M 66 70 40
15 M 76 87 62
16 M 82 119 74
17 F 71 106 45
18 M 72 N/A N/A
19 M 71 N/A N/A
20 F 63 68.7 37.3
21 M 77 86 56
22 M 73 52 N/A
23 F 65 80 57
24 M 77 101 62
25 M 86 104 70
N/A not applicable
a Pulmonary function test data are percentage predicted
Axial Sagittal CoronalFig. 1 PET/CT images in a
patient with IPF. A region of
interest is drawn on normal lung
parenchyma shown on the CT
images (upper row). Normality
was confirmed by an
experienced (>10 years) thoracic
radiologist. Corresponding PET
images (lower row) with the
region of interest superimposed
allow quantification of 18F-FDG
uptake
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PET/64-detector CT instrument (GE Healthcare Technology,
Waukesha, WI). In total, three sequential imaging se-
quences of the thorax were performed whilst the patient
remained supine on the table throughout. Firstly, a CT
scan was performed for attenuation correction using 64×3.75-
mm detectors, a pitch of 1.5 and a 5-mm collimation (140 kVp
and 80 mA in 0.8 s). Maintaining the patient position, a
whole-body 18F-FDG PET emission scan was performed
covering an area identical to that covered by the CT
scan. All acquisitions were carried out in 2-D mode
(8 min per bed position). Transaxial emission images of
3.27-mm thickness (pixel size 3.9 mm) were reconstructed
using ordered subsets expectation maximization with two
iterations and 28 subsets. The axial field of view was
148.75 mm, resulting in 47 slices per bed position. Next,
maintaining the patient position, a deep inspiratory HRCT
scan was performed using 64×1.25-mm detectors, a pitch of
0.53 and 1.25-mm collimation (120 kVp and 100 mAs).
Image analysis
Observers
Images were analysed by a physicist with >3 years’ experience,
a PET radiologist with >5 years’ experience and a senior PET
technologist with >5 years’ experience in quantifying pulmo-
nary PET images in IPF patients. All corresponding CT images
were analysed for normality by a dedicated chest radiologist
with a >10 years’ special interest in HRCT and >5 years’
experience at analysing CT and HRCT with PET scans in IPF
patients.
Image display and processing
All images were loaded onto a proprietary workstation. All
datasets underwent registration [12] to take into account
respiratory mismatches between PET and CT studies as
previously described [13, 14]. A single volume of interest
(VOI) was placed in each lung in areas considered morpho-
logically normal. Care was taken to identify normal regions
of lung identifiable over several transverse slices, remote
from major blood vessels and airways (see Fig. 1). In most
subjects regions were defined in the middle lobe; in some
subjects ‘normal’ regions could only be identified closer to
the apex. Relatively small regions were defined so as to
avoid spill-over from adjacent tissues. Care was also taken
to select the central slices from the subvolume containing
normal lung so as to minimize the effects of axial motion. In
IPF subjects, normal regions corresponded to areas of min-
imal observed density as distinct from regions that were
identifiable as having either ground glass or honeycomb
patterns or more diffuse increases in density. Observers were
requested to define VOIs with a target volume of 20 cm3. In
subjects in whom a volume of this size was not identifiable,
smaller VOIs were selected. The median (range) VOI in the
control group was 21.23 cm3 (17.05 – 22.01 cm3) and in the
IPF group was 19.37 cm3 (15.31 – 22.01 cm3). VOIs were
then used on the coregistered PET studies to determine the
mean SUV within each VOI. Analysis was performed on the
datasets with and without correction for tissue fraction (TF)
in order to account for the variable amount of air in different
lung regions (both within individuals and across the subjects
studied), as described previously [13, 14].
Statistical analysis
Control and patient groups were compared in terms of mean
Hounsfield units andmean SUV,with andwithout TF correction,
using two-tailed t tests, assuming unequal variance. The
intragroup variability, with and without TF correction, was also
reported in terms of coefficient of variation (CoV), calculated as
the group SD divided by the group mean.
Fig. 2 Pulmonary parenchyma CT densities (Hounsfield units) in IPF
and control subjects (error bars mean ± SD)
Table 2 CT densities (Hounsfield
units) in pulmonary regions se-
lected as normal on CT scans in
IPF and control subjects
Group CT density (HU) p value 95 % confidence interval
Mean SD Lower bound Upper bound
Control −765.97 51.54 0.08 −786.17 −745.77
IPF −738.64 57.60 −761.22 −716.06
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Results
No significant difference in SUV was found between the
lymphoma and paraneoplasia groups. This was true both
for uncorrected SUV (lymphoma group 0.45±0.13; para-
neoplasia group 0.51±0.14, mean ± SD; p=0.25) and TF-
corrected mean SUV (lymphoma group 2.07±0.30;
paraneoplasia group 2.27±0.31; p=0.11). This justified the
combination of the lymphoma and paraneoplasia groups into
a single control group.
The pulmonary parenchyma CT densities (Hounsfield units)
of the control groups and the IPF patients were not significantly
different (Fig. 2 and Table 2; p=0.08), supporting the visual
selection of normal regions in IPF patients as assessed by the
HRCT expert reporter.
The difference in mean SUV between the combined con-
trol group and the IPF group were highly significant both for
data uncorrected for TF (0.48±0.14 versus 0.78±0.24;
Table 3 and Fig. 3a; p<0.00001) and for data corrected for
TF (2.24±0.29 versus 3.24±0.84; Table 3 and Fig. 3b;
p<0.00001). The CoVs of the uncorrected data of the two
groups were 0.29 for the combined control group and 0.31
for the IPF group. After TF correction, the CoVs reduced to
0.13 for the control group and 0.26 for the IPF subjects.
Discussion
These data show that in IPF there is increased pulmonary
uptake of 18F-FDG on PETeven in those areas with a normal
morphological appearance of the lung parenchyma on
HRCT. Our analysis of the CT data confirmed that the
selected normal regions in IPF patients were appropriate,
yielding Hounsfield unit values consistent with those of the
normal group. This implies that PET may have a higher
sensitivity in the detection of early pulmonary disease in
IPF than HRCT. This has possible implications for under-
standing the in vivo pathogenesis of IPF and may be impor-
tant in early disease detection and treatment monitoring. The
pathogenesis of IPF remains poorly understood [1–4]. Our
finding that there is diffuse hypermetabolism implies that the
parenchyma is globally affected in IPF. How this can be
reconciled with HRCTchanges that predominate in the lower
lobe and peripherally is uncertain, but it is recognized that
the pathological changes in IPF are both spatially and tem-
porally heterogeneous. The cell type accounting for the
metabolic signal on FDG PET also remains unclear. The
presence of diffusely raised pulmonary 18F-FDG uptake,
even in areas of normal parenchyma on HRCT, renders
hypotheses suggesting that the PET signal in IPF patients is
Fig. 3 Mean pulmonary SUVs
in IPF and control subjects (a
uncorrected for TF, b corrected
for TF; error bars mean ± SD)
Table 3 Uncorrected and TF-
corrected mean SUVs using the
normal part of IPF lungs in the
comparison. The p values reflect
the significance of the difference
between the control and IPF
groups
TF correction Group SUV p value 95 % confidence interval
Mean SD Lower bound Upper bound
Uncorrected Control 0.48 0.14 0.00000423 0.43 0.54
IPF 0.78 0.24 0.69 0.88
Corrected Control 2.24 0.29 0.00000434 2.13 2.36
IPF 3.24 0.84 2.91 3.57
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predominantly caused by colonization of polymorph infiltra-
tion secondary to infection in dilated airways less likely.
Moreover, the fact that fibroblasts are generally sparse in
normal lung [15] may suggest that this cell type is not
responsible for the PET signal.
We present the first evidence in IPF patients that PET can
detect abnormalities in the absence of HRCT lung parenchy-
mal changes. This suggests that PET may be more sensitive
than HRCT in detecting early disease, and in turn, this may
allow early detection of therapeutic response. It has been
shown [16, 17] that honeycombing and reticulation changes
on HRCT are associated with microscopic changes of fibro-
sis (usual interstitial pneumonia pattern). Once the disease
has reached this stage, it would be challenging to reverse the
process. However, detecting earlier disease signals may help
reveal upstream metabolic targets for switching off the fi-
brotic drive. In this respect, the role of TGF-beta and integrin
metabolism is becoming increasingly recognized in IPF and
thus there is potential for antagonists such as those against
alpha v beta 6 ligands to modify the disease process [18].
In the development of such therapeutics for IPF, our PET
findings may play a role by potentially offering early disease
detection and monitoring of therapeutic response to treat-
ment. There are no effective treatments and drug discovery
trials are limited by the only current reliable endpoint of
mortality. Since mortality is a relatively long endpoint (typ-
ically >2 years), this is a considerable barrier to therapeutic
development [1–4]. Given that it has been shown that the
pulmonary PET signal in IPF is stable over time [14], this
would further support the development of PET as a surrogate
endpoint for future clinical trials.
We have previously drawn attention to the importance of
correcting for the variable air volume in the lung by
performing TF correction [13]. In this study applying this
correction increased the difference between the disease and
control groups, while reducing intragroup variability. This
suggests that TF correction may be important in maximizing
sensitivity to detection of early disease.
The study limitations include the lack of data from normal
volunteers. However, given the radiation exposure from 18F-
FDG PET/CT, there would be ethical concerns in acquiring
data from healthy patients. Similarly, HRCT was not
performed in the control population due to the associated
increase in CT dose. This may have reduced the accuracy of
VOI placement in the controls compared to that in the IPF
patients who all had HRCT data available. The age and sex
profile of the IPF patients make it difficult to find suitable
control groups matched for age and sex. We therefore select-
ed the 25 oldest subjects (male and female) from our two
control cohorts. We found no significant differences in the
results between the two patient subgroups used for controls.
There was some heterogeneity in the patients with IPF, such
as administered medications, which may have altered the
pulmonary SUVmeasurements. However, a degree of hetero-
geneity is always present in IPF/DPLD populations and our
population was relatively homogeneous compared to others.
No respiratory gating was employed in the study and so there
is the possibility of mismatch between the PET data (which is
averaged over the respiratory cycle) and the short-acquisition
CT study. The datasets were registered to minimize differ-
ences between the studies. Also relatively small regions were
defined to accommodate the fact that SUV values represent
average values for tissue extending beyond the defined re-
gions as a result of respiratory motion.
Conclusion
IPF patients have increased pulmonary uptake of 18F-FDG on
PET at sites with normal morphological appearance on lung
HRCT. These findings may have implications for the under-
standing of the pathogenesis of this disease and its treatment.
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